サマリー

市場分析とインサイト。選択的アゴニストの世界市場
選択的アゴニストの世界市場規模は、2020年のXX百万米ドルから2021-2027年の間にXX％のCAGRで、2027年にはXX百万米ドルに達すると予測されています。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界の選択的アゴニスト市場で得られる主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つよう、見事な試みを行っています。本レポートの購入者は、検証された信頼性の高い市場予測にアクセスすることができ、その中には収益面での選択的アゴニストの世界市場全体のサイズも含まれています。
本レポートは、選択的アゴニストの世界市場において、競合他社に対して優位に立ち、永続的な成功を収めるための効果的なツールであることを証明しています。本レポートに掲載されている調査結果、データ、情報はすべて、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、選択的アゴニストの世界市場を詳細に調査するために、独自の、そして業界で最も優れた調査・分析手法を用いています。

世界の選択的アゴニストの範囲と市場規模
選択的アゴニスト市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界の選択的アゴニスト市場に参加するプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間におけるタイプ別、アプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
α1選択的アゴニスト
α2選択的アゴニスト
β1選択的アゴニスト
β2選択的アゴニスト

用途別セグメント
発作性上室性頻拍
点眼薬
アナフィラキシー
心筋梗塞
アナフィラキシー
心停止
慢性心不全
心筋梗塞
術後低血圧

地域別
北アメリカ
U.S.
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
メルク
バウシュ・ヘルス社
ファイザー
スターリング・ウィンスロップ
サノフィ
パラゴン・バイオテック
ウエストワード・ファーマシューティカルズ
バイオシエント・ファーマ
ノバルティス
オメガラボラトリーズ
メディカル・パーチェシング・ソリューションズ
アヴァデル・レガシー・ファーマシューティカルズ
アムネールバイオサイエンス
シプラUSA
パー・ファーマシューティカル
Glaxosmithkline
テバ
バイエル
インパックス・ジェネリックス
マイラン製薬
フィジシャンズトータルケア
カディラ・ファーマシューティカルズ（Cadila Pharnmaceuticals
アレンビック・ファーマシューティカルズ
アラガン社
マイラン

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Selective Agonists Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 α1 Selective Agonists
1.2.3 α2 Selective Agonists
1.2.4 β1 Selective Agonists
1.2.5 β2 Selective Agonists
1.3 Market by Application
1.3.1 Global Selective Agonists Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Paroxysmal Supraventricular Tachycardia
1.3.3 Eye Drops
1.3.4 Anaphylaxis
1.3.5 Cardiac Arrest
1.3.6 Anaphylaxis
1.3.7 Cardiac Arrest
1.3.8 Chronic Heart Failure
1.3.9 Myocardial Infarction
1.3.10 Postoperative Hypotension
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Selective Agonists Market Perspective (2016-2027)
2.2 Selective Agonists Growth Trends by Regions
2.2.1 Selective Agonists Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Selective Agonists Historic Market Share by Regions (2016-2021)
2.2.3 Selective Agonists Forecasted Market Size by Regions (2022-2027)
2.3 Selective Agonists Industry Dynamic
2.3.1 Selective Agonists Market Trends
2.3.2 Selective Agonists Market Drivers
2.3.3 Selective Agonists Market Challenges
2.3.4 Selective Agonists Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Selective Agonists Players by Revenue
3.1.1 Global Top Selective Agonists Players by Revenue (2016-2021)
3.1.2 Global Selective Agonists Revenue Market Share by Players (2016-2021)
3.2 Global Selective Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Selective Agonists Revenue
3.4 Global Selective Agonists Market Concentration Ratio
3.4.1 Global Selective Agonists Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Selective Agonists Revenue in 2020
3.5 Selective Agonists Key Players Head office and Area Served
3.6 Key Players Selective Agonists Product Solution and Service
3.7 Date of Enter into Selective Agonists Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Selective Agonists Breakdown Data by Type
4.1 Global Selective Agonists Historic Market Size by Type (2016-2021)
4.2 Global Selective Agonists Forecasted Market Size by Type (2022-2027)

5 Selective Agonists Breakdown Data by Application
5.1 Global Selective Agonists Historic Market Size by Application (2016-2021)
5.2 Global Selective Agonists Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Selective Agonists Market Size (2016-2027)
6.2 North America Selective Agonists Market Size by Type
6.2.1 North America Selective Agonists Market Size by Type (2016-2021)
6.2.2 North America Selective Agonists Market Size by Type (2022-2027)
6.2.3 North America Selective Agonists Market Size by Type (2016-2027)
6.3 North America Selective Agonists Market Size by Application
6.3.1 North America Selective Agonists Market Size by Application (2016-2021)
6.3.2 North America Selective Agonists Market Size by Application (2022-2027)
6.3.3 North America Selective Agonists Market Size by Application (2016-2027)
6.4 North America Selective Agonists Market Size by Country
6.4.1 North America Selective Agonists Market Size by Country (2016-2021)
6.4.2 North America Selective Agonists Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Selective Agonists Market Size (2016-2027)
7.2 Europe Selective Agonists Market Size by Type
7.2.1 Europe Selective Agonists Market Size by Type (2016-2021)
7.2.2 Europe Selective Agonists Market Size by Type (2022-2027)
7.2.3 Europe Selective Agonists Market Size by Type (2016-2027)
7.3 Europe Selective Agonists Market Size by Application
7.3.1 Europe Selective Agonists Market Size by Application (2016-2021)
7.3.2 Europe Selective Agonists Market Size by Application (2022-2027)
7.3.3 Europe Selective Agonists Market Size by Application (2016-2027)
7.4 Europe Selective Agonists Market Size by Country
7.4.1 Europe Selective Agonists Market Size by Country (2016-2021)
7.4.2 Europe Selective Agonists Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Selective Agonists Market Size (2016-2027)
8.2 Asia-Pacific Selective Agonists Market Size by Type
8.2.1 Asia-Pacific Selective Agonists Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Selective Agonists Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Selective Agonists Market Size by Type (2016-2027)
8.3 Asia-Pacific Selective Agonists Market Size by Application
8.3.1 Asia-Pacific Selective Agonists Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Selective Agonists Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Selective Agonists Market Size by Application (2016-2027)
8.4 Asia-Pacific Selective Agonists Market Size by Region
8.4.1 Asia-Pacific Selective Agonists Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Selective Agonists Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Selective Agonists Market Size (2016-2027)
9.2 Latin America Selective Agonists Market Size by Type
9.2.1 Latin America Selective Agonists Market Size by Type (2016-2021)
9.2.2 Latin America Selective Agonists Market Size by Type (2022-2027)
9.2.3 Latin America Selective Agonists Market Size by Type (2016-2027)
9.3 Latin America Selective Agonists Market Size by Application
9.3.1 Latin America Selective Agonists Market Size by Application (2016-2021)
9.3.2 Latin America Selective Agonists Market Size by Application (2022-2027)
9.3.3 Latin America Selective Agonists Market Size by Application (2016-2027)
9.4 Latin America Selective Agonists Market Size by Country
9.4.1 Latin America Selective Agonists Market Size by Country (2016-2021)
9.4.2 Latin America Selective Agonists Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Selective Agonists Market Size (2016-2027)
10.2 Middle East & Africa Selective Agonists Market Size by Type
10.2.1 Middle East & Africa Selective Agonists Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Selective Agonists Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Selective Agonists Market Size by Type (2016-2027)
10.3 Middle East & Africa Selective Agonists Market Size by Application
10.3.1 Middle East & Africa Selective Agonists Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Selective Agonists Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Selective Agonists Market Size by Application (2016-2027)
10.4 Middle East & Africa Selective Agonists Market Size by Country
10.4.1 Middle East & Africa Selective Agonists Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Selective Agonists Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Selective Agonists Introduction
11.1.4 Merck Revenue in Selective Agonists Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Bausch Health Companies
11.2.1 Bausch Health Companies Company Details
11.2.2 Bausch Health Companies Business Overview
11.2.3 Bausch Health Companies Selective Agonists Introduction
11.2.4 Bausch Health Companies Revenue in Selective Agonists Business (2016-2021)
11.2.5 Bausch Health Companies Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Selective Agonists Introduction
11.3.4 Pfizer Revenue in Selective Agonists Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Sterling Winthrop
11.4.1 Sterling Winthrop Company Details
11.4.2 Sterling Winthrop Business Overview
11.4.3 Sterling Winthrop Selective Agonists Introduction
11.4.4 Sterling Winthrop Revenue in Selective Agonists Business (2016-2021)
11.4.5 Sterling Winthrop Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Selective Agonists Introduction
11.5.4 Sanofi Revenue in Selective Agonists Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Paragon BioTeck
11.6.1 Paragon BioTeck Company Details
11.6.2 Paragon BioTeck Business Overview
11.6.3 Paragon BioTeck Selective Agonists Introduction
11.6.4 Paragon BioTeck Revenue in Selective Agonists Business (2016-2021)
11.6.5 Paragon BioTeck Recent Development
11.7 West-Ward Pharmaceuticals 
11.7.1 West-Ward Pharmaceuticals  Company Details
11.7.2 West-Ward Pharmaceuticals  Business Overview
11.7.3 West-Ward Pharmaceuticals  Selective Agonists Introduction
11.7.4 West-Ward Pharmaceuticals  Revenue in Selective Agonists Business (2016-2021)
11.7.5 West-Ward Pharmaceuticals  Recent Development
11.8 Biosyent Pharma 
11.8.1 Biosyent Pharma  Company Details
11.8.2 Biosyent Pharma  Business Overview
11.8.3 Biosyent Pharma  Selective Agonists Introduction
11.8.4 Biosyent Pharma  Revenue in Selective Agonists Business (2016-2021)
11.8.5 Biosyent Pharma  Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Selective Agonists Introduction
11.9.4 Novartis Revenue in Selective Agonists Business (2016-2021)
11.9.5 Novartis Recent Development
11.10 Omega Laboratories
11.10.1 Omega Laboratories Company Details
11.10.2 Omega Laboratories Business Overview
11.10.3 Omega Laboratories Selective Agonists Introduction
11.10.4 Omega Laboratories Revenue in Selective Agonists Business (2016-2021)
11.10.5 Omega Laboratories Recent Development
11.11 Medical Purchasing Solutions
11.11.1 Medical Purchasing Solutions Company Details
11.11.2 Medical Purchasing Solutions Business Overview
11.11.3 Medical Purchasing Solutions Selective Agonists Introduction
11.11.4 Medical Purchasing Solutions Revenue in Selective Agonists Business (2016-2021)
11.11.5 Medical Purchasing Solutions Recent Development
11.12 Avadel Legacy Pharmaceuticals
11.12.1 Avadel Legacy Pharmaceuticals Company Details
11.12.2 Avadel Legacy Pharmaceuticals Business Overview
11.12.3 Avadel Legacy Pharmaceuticals Selective Agonists Introduction
11.12.4 Avadel Legacy Pharmaceuticals Revenue in Selective Agonists Business (2016-2021)
11.12.5 Avadel Legacy Pharmaceuticals Recent Development
11.13 Amneal Biosciences
11.13.1 Amneal Biosciences Company Details
11.13.2 Amneal Biosciences Business Overview
11.13.3 Amneal Biosciences Selective Agonists Introduction
11.13.4 Amneal Biosciences Revenue in Selective Agonists Business (2016-2021)
11.13.5 Amneal Biosciences Recent Development
11.14 Cipla USA
11.14.1 Cipla USA Company Details
11.14.2 Cipla USA Business Overview
11.14.3 Cipla USA Selective Agonists Introduction
11.14.4 Cipla USA Revenue in Selective Agonists Business (2016-2021)
11.14.5 Cipla USA Recent Development
11.15 Par Pharmaceutical
11.15.1 Par Pharmaceutical Company Details
11.15.2 Par Pharmaceutical Business Overview
11.15.3 Par Pharmaceutical Selective Agonists Introduction
11.15.4 Par Pharmaceutical Revenue in Selective Agonists Business (2016-2021)
11.15.5 Par Pharmaceutical Recent Development
11.16 Glaxosmithkline
11.16.1 Glaxosmithkline Company Details
11.16.2 Glaxosmithkline Business Overview
11.16.3 Glaxosmithkline Selective Agonists Introduction
11.16.4 Glaxosmithkline Revenue in Selective Agonists Business (2016-2021)
11.16.5 Glaxosmithkline Recent Development
11.17 Teva
11.17.1 Teva Company Details
11.17.2 Teva Business Overview
11.17.3 Teva Selective Agonists Introduction
11.17.4 Teva Revenue in Selective Agonists Business (2016-2021)
11.17.5 Teva Recent Development
11.18 Bayer
11.18.1 Bayer Company Details
11.18.2 Bayer Business Overview
11.18.3 Bayer Selective Agonists Introduction
11.18.4 Bayer Revenue in Selective Agonists Business (2016-2021)
11.18.5 Bayer Recent Development
11.18 Impax Generics
11.25.1 Impax Generics Company Details
11.25.2 Impax Generics Business Overview
11.25.3 Impax Generics Selective Agonists Introduction
11.25.4 Impax Generics Revenue in Selective Agonists Business (2016-2021)
11.25.5 Impax Generics Recent Development
11.20 Mylan Pharmaceuticals
11.20.1 Mylan Pharmaceuticals Company Details
11.20.2 Mylan Pharmaceuticals Business Overview
11.20.3 Mylan Pharmaceuticals Selective Agonists Introduction
11.20.4 Mylan Pharmaceuticals Revenue in Selective Agonists Business (2016-2021)
11.20.5 Mylan Pharmaceuticals Recent Development
11.21 Physicians Total Care
11.21.1 Physicians Total Care Company Details
11.21.2 Physicians Total Care Business Overview
11.21.3 Physicians Total Care Selective Agonists Introduction
11.21.4 Physicians Total Care Revenue in Selective Agonists Business (2016-2021)
11.21.5 Physicians Total Care Recent Development
11.22 Cadila Pharnmaceuticals
11.22.1 Cadila Pharnmaceuticals Company Details
11.22.2 Cadila Pharnmaceuticals Business Overview
11.22.3 Cadila Pharnmaceuticals Selective Agonists Introduction
11.22.4 Cadila Pharnmaceuticals Revenue in Selective Agonists Business (2016-2021)
11.22.5 Cadila Pharnmaceuticals Recent Development
11.23 Alembic Pharmaceuticals
11.23.1 Alembic Pharmaceuticals Company Details
11.23.2 Alembic Pharmaceuticals Business Overview
11.23.3 Alembic Pharmaceuticals Selective Agonists Introduction
11.23.4 Alembic Pharmaceuticals Revenue in Selective Agonists Business (2016-2021)
11.23.5 Alembic Pharmaceuticals Recent Development
11.24 Allergan
11.24.1 Allergan Company Details
11.24.2 Allergan Business Overview
11.24.3 Allergan Selective Agonists Introduction
11.24.4 Allergan Revenue in Selective Agonists Business (2016-2021)
11.24.5 Allergan Recent Development
11.25 Mylan
11.25.1 Mylan Company Details
11.25.2 Mylan Business Overview
11.25.3 Mylan Selective Agonists Introduction
11.25.4 Mylan Revenue in Selective Agonists Business (2016-2021)
11.25.5 Mylan Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details